Adalimumab passes to newborn

Article from the health outcomes explored at Digestive Disease Week 2011 shows that infants exposed in utero to Adalimumab, aka Humira, will have it linger in their system and it will be in the cord blood:

“At a minimum, it can be detected to three months from birth,” Dr. Mahadevan noted.